Table 6.
Areal bone mineral density, bone geometry, and microstructure in women with SSRI treatment and matched controls
| DXA | SSRI No | SSRI Yes | p-value | Standardized beta | Adjusted p-value |
|---|---|---|---|---|---|
| (n = 343) | (n = 86) | ||||
| Femoral neck aBMD (g/cm2) | 0.65 ± 0.1 | 0.68 ± 0.1 | 0.01 | 0.13 | 0.01 |
| Total Hip aBMD (g/cm2) | 0.79 ± 0.1 | 0.83 ± 0.1 | 0.01 | 0.13 | 0.01 |
| Lumbar spine aBMD (g/cm2) | 0.94 ± 0.2 | 1.00 ± 0.2 | 0.001 | 0.15 | 0.002 |
| HR-pQCT | |||||
|---|---|---|---|---|---|
| Tibia ultradistal | (n = 336) | (n = 81) | |||
| Trabecular bone volume fraction (%) | 12.1 ± 3.0 | 12.6 ± 2.8 | 0.17 | 0.07 | 0.16 |
| Trabecular thickness (mm) | 0.07 ± 0.01 | 0.07 ± 0.01 | 0.64 | 0.04 | 0.46 |
| Trabecular separation (mm) | 0.52 ± 0.18 | 0.50 ± 0.14 | 0.31 | − 0.05 | 0.33 |
| Trabecular number (mm−1) | 1.80 ± 0.37 | 1.84 ± 0.35 | 0.33 | 0.04 | 0.43 |
| Cortical area (mm2) | 76.9 ± 23.7 | 74.0 ± 21.3 | 0.32 | − 0.05 | 0.36 |
| Cortical volumetric BMD (mg/cm3) | 736 ± 71.0 | 733 ± 62.6 | 0.77 | − 0.01 | 0.85 |
| Cortical thickness (mm) | 0.73 ± 0.25 | 0.70 ± 0.22 | 0.32 | − 0.05 | 0.37 |
| Cortical porosity (%) | 10.4 ± 2.92 | 10.6 ± 2.93 | 0.59 | 0.04 | 0.52 |
| HR-pQCT | |||||
|---|---|---|---|---|---|
| Tibia distal (14% of bone length) | (n = 341) | (n = 82) | |||
| Cortical area (mm2) | 148 ± 25.4 | 148 ± 24.0 | 0.99 | − 0.0001 | 1.00 |
| Cortical volumetric BMD (mg/cm3) | 914 ± 43.8 | 919 ± 43.1 | 0.39 | 0.05 | 0.34 |
| Cortical thickness (mm) | 1.80 ± 0.33 | 1.80 ± 0.30 | 0.95 | − 0.001 | 0.98 |
| Cortical porosity (%) | 4.71 ± 2.18 | 4.56 ± 2.07 | 0.62 | − 0.04 | 0.49 |
| HR-pQCT | |||||
|---|---|---|---|---|---|
| Radius ultradistal | (n = 278) | (n = 70) | |||
| Trabecular bone volume fraction (%) | 9.86 ± 3.33 | 10.6 ± 3.62 | 0.12 | 0.10 | 0.07 |
| Trabecular thickness (mm) | 0.06 ± 0.01 | 0.06 ± 0.01 | 0.56 | 0.05 | 0.37 |
| Trabecular separation (mm) | 0.59 ± 0.26 | 0.55 ± 0.21 | 0.22 | − 0.07 | 0.19 |
| Trabecular number (mm−1) | 1.69 ± 0.43 | 1.78 ± 0.45 | 0.14 | 0.08 | 0.13 |
| Cortical area (mm2) | 37.4 ± 12.2 | 37.2 ± 9.77 | 0.93 | − 0.01 | 0.81 |
| Cortical volumetric BMD (mg/cm3) | 764 ± 79.2 | 770 ± 69.3 | 0.51 | 0.03 | 0.53 |
| Cortical thickness (mm) | 0.54 ± 0.16 | 0.53 ± 0.19 | 0.68 | 0.01 | 0.82 |
| Cortical porosity (%) | 3.78 ± 1.59 | 3.70 ± 1.71 | 0.73 | − 0.02 | 0.73 |
| HR-pQCT | |||||
|---|---|---|---|---|---|
| Radius distal (14% of bone length) | (n = 311) | (n = 77) | |||
| Cortical area (mm2) | 59.8 ± 11.0 | 59.8 ± 10.1 | 0.98 | 0.002 | 0.97 |
| Cortical volumetric BMD (mg/cm3) | 1004 ± 38.9 | 1002 ± 35.7 | 0.65 | − 0.002 | 0.97 |
| Cortical thickness (mm) | 1.32 ± 0.21 | 1.33 ± 0.19 | 0.76 | 0.02 | 0.69 |
| Cortical porosity (%) | 1.89 ± 1.38 | 1.98 ± 1.62 | 0.65 | 0.02 | 0.78 |
Statistically significant values (p < 0.05) are given in bold
An independent samples t test was used to compare differences in indices of bone variables between matched SSRI-users and non-users. Differences in these variables were also investigated in linear regression models, adjusted for mental health (MCS), physical health (PCS), oral glucocorticoid treatment, rheumatoid arthritis, current smoking, high alcohol consumption (more than three standard drinks per day), parental hip fracture, and previous fractures. Results for the linear regressions are presented as standardized beta
SSRI selective serotonin reuptake inhibitor, aBMD areal bone mineral density, HR-pQCT high-resolution peripheral quantitative computed tomography, Ultradistal HR-pQCT measurements according to the manufacturer, Distal HR-pQCT measurements at 14% of tibia bone length